Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients

Federal University of São Paulo60 enrolled

Overview

The purpose of this study is to compare the efficacy and safety of intra-articular glucocorticoid injection to its systemic use for treatment of knee synovitis in patients with Rheumatoid Arthritis

A randomized double-blind controlled study was conducted including 60 patients with RA. Patients were randomized to receive either a single intra-articular knee injection with triamcinolone hexacetonide 60 mg and xylocaine chloride 2% (1 mL) associated to a single intramuscular injection of 1 mL of xylocaine chloride 2% (IAI group) or 1 mL of xylocaine chloride 2% by intra-articular injection and a intramuscular injection of triamcinolone acetonide 60 mg and xylocaine chloride 2% (1 mL) (IM group). Evaluations were performed at baseline and 1, 4, 8 and 12 weeks post-intervention. The following instruments were used: the ACR 20%, 50 and 70% improvement criteria; VAS for knee morning stiffness, pain and edema; knee circumference and goniometry; Likert's scale of improvement (IVAS); daily use of oral glucocorticoid and NSAIDs, blood pressure and adverse effects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

intraarticular injectionDRUG

Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Rheumatoid Arthritis diagnosed for more than 6 months * 18 and 65 years * Functional class II or III according to the ACR criteria * VAS for knee pain higher than 5 * Use of stable doses of oral corticosteroid for the last 30 days * Use of stable doses of DMARDs for the last 3 months * Active synovitis at least in one knee for at least the 30 days Exclusion Criteria: * Non-controlled diabetes mellitus or hypertension * Bacterial infection of any site * Blood coagulation disorders * Skin lesion on the affected knee * History of previous surgical procedure in the knee * Use of intra-muscular glucocorticoid in the last 30 days * Intra-articular injection in the last 3 months * Knee injection in the last 6 months

Locations (1)

Rheumatology Division, Federal University of Sao Paulo

São Paulo, São Paulo, Brazil

Outcomes

Primary Outcomes

VAS for knee pain

Time frame: 12 weeks post intervention

Secondary Outcomes

side and adverse effects, safety

Time frame: 12 weeks post intervention

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.